Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000
Debt
Debt-to-Equity Ratio0.17
Current Ratio4.33
Quick Ratio3.28
Price-To-Earnings
Trailing P/E Ratio-4.93
Forward P/E Ratio-6.40
P/E GrowthN/A
Sales & Book Value
Annual Sales$93.47 million
Price / Sales6.06
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book5.80
Profitability
EPS (Most Recent Fiscal Year)($0.87)
Net Income$-92,180,000.00
Net Margins-100.09%
Return on Equity-95.29%
Return on Assets-60.07%
Miscellaneous
Employees456
Outstanding Shares131,940,000
Market Cap$577.91 million
Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions
What is Pacific Biosciences of California's stock symbol?
Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."
How were Pacific Biosciences of California's earnings last quarter?
Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings data on Thursday, August, 2nd. The biotechnology company reported ($0.17) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.17). The biotechnology company earned $21.58 million during the quarter, compared to the consensus estimate of $24.45 million. Pacific Biosciences of California had a negative return on equity of 95.29% and a negative net margin of 100.09%. The company's quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.26) earnings per share. View Pacific Biosciences of California's Earnings History.
When is Pacific Biosciences of California's next earnings date?
How can I listen to Pacific Biosciences of California's earnings call?
Pacific Biosciences of California will be holding an earnings conference call on Thursday, November 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8883667247.
What price target have analysts set for PACB?
4 brokerages have issued 1-year price targets for Pacific Biosciences of California's shares. Their predictions range from $3.80 to $8.00. On average, they expect Pacific Biosciences of California's stock price to reach $5.5750 in the next year. This suggests a possible upside of 30.0% from the stock's current price. View Analyst Price Targets for Pacific Biosciences of California.
What is the consensus analysts' recommendation for Pacific Biosciences of California?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pacific Biosciences of California.
What are Wall Street analysts saying about Pacific Biosciences of California stock?
Here are some recent quotes from research analysts about Pacific Biosciences of California stock:
- 1. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $8 PT on shares of PACB. Last week (Oct. 16-18), we attended the Genetics (ASHG) annual meeting in San Diego. Our overall impression from the conference is our continued belief that science is just scratching the surface with next-generation sequencing (NGS) and its application in medicine. At the conference we met with PacBio management, and we attended PacBio’s exhibitor education event that was open to all conference attendees. Below we highlight our conference takeaways and answer top investor questions we’ve received since we launched coverage." (10/21/2018)
- 2. According to Zacks Investment Research, "Pacific Biosciences saw a dreary second quarter. However, the company witnessed strong bookings for Sequel in the quarter. Constant instrument orders from BGI and China are encouraging. Furthermore, the company is well poised on expansion of SMRT Sequencing and product development activities. On the flip side, Product and service revenues deteriorated on a year-over-year basis due to lower instrument revenues. Dull performance in the other revenue segment is a concern. The DNA sequencing market is rife with competition. Sales in Europe declined considerably. Also, higher operating expenses are a headwind. The stock is currently overvalued. The company has also not provided any guidance for the upcoming quarters. Pacific Biosciences has underperformed the industry in a year’s time. Pacific Biosciences underperformed the industry in a year’s time." (8/6/2018)
Are investors shorting Pacific Biosciences of California?
Pacific Biosciences of California saw a decline in short interest during the month of September. As of September 14th, there was short interest totalling 8,135,336 shares, a decline of 13.5% from the August 31st total of 9,402,535 shares. Based on an average daily trading volume, of 1,914,906 shares, the short-interest ratio is presently 4.2 days. Currently, 6.9% of the company's shares are sold short. View Pacific Biosciences of California's Current Options Chain.
Who are some of Pacific Biosciences of California's key competitors?
Some companies that are related to Pacific Biosciences of California include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND), Bio-Rad Laboratories, Inc. Class B (BIO.B), Horiba (HRIBF) and PositiveID (PSID).
Who are Pacific Biosciences of California's key executives?
Pacific Biosciences of California's management team includes the folowing people:
- Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 69)
- Ms. Susan K. Barnes, Sr. VP & CFO (Age 64)
- Mr. James Michael Phillips, Sr. VP of R&D (Age 67)
- Mr. Kevin P. Corcoran, Sr. VP of Market Devel. (Age 59)
- Ms. Kathy P. Ordoñez, Chief Commercial Officer, Exec. VP & Director (Age 67)
How do I buy shares of Pacific Biosciences of California?
Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacific Biosciences of California's stock price today?
One share of PACB stock can currently be purchased for approximately $4.29.
How big of a company is Pacific Biosciences of California?
Pacific Biosciences of California has a market capitalization of $577.91 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.
What is Pacific Biosciences of California's official website?
How can I contact Pacific Biosciences of California?
Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]
MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
